Key result
Tavapadon evaluation in TEMPO-4 lacks specific clinical results for levodopa use in Parkinson's disease.
Tavapadon’s effect on levodopa use in PD remains unquantified from open-label data; leaves open need for randomized trials.
To evaluate changes in levodopa use among adults with Parkinson’s disease (PD) receiving tavapadon in the TEMPO-4 trial (NCT04760769).
No takes yet. Share an insight, caveat, or question.
Ondo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: